# Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B

> **NCT01925820** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 540 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Pegasys&Entecavir

## Key facts

- **NCT ID:** NCT01925820
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2018-12
- **Final completion:** —
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2014-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925820, "Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01925820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*